Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis

Blood (2024) 143 (26): 2735–2748.

https://doi.org/10.1182/blood.2023021088

Published: 2024

Includes: Supplemental data

Journal Articles

Drug Response Profiling Informs Personalized Bridging to Cell Therapy for Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 4350.

https://doi.org/10.1182/blood-2023-179306

Published: 2023

Journal Articles

Phenotypic Drug Response Profiling Identifies Asparaginase-Based Synergistic Combinations for Very High Risk Acute Lymphoblastic Leukaemia

Jasmeet Sidhu, Fabio D. Steffen, Iria Anne Jimenez, Yun Huang, Kerstin K. Rauwolf, Arijit Chakraborty, Shekhar Krishnan, Vaskar Saha, Beat Bornhauser, Jean-Pierre Bourquin

Blood (2023) 142 (Supplement 1): 417.

https://doi.org/10.1182/blood-2023-172885

Published: 2023

Journal Articles

Delayed Intensification Including Venetoclax and Bortezomib Prolongs Survival in Very High Risk Acute Lymphoblastic Leukaemia

Jasmeet Sidhu, Arijit Chakraborty, Parag Das, Manash Pratim Gogoi, Tanima Dey, Fabio D. Steffen, Sangramjit Basu, Debdutta Ganguli, Debjani Ghosh, Niharendu Ghara, Subhajit Kundu, Abhirupa Kar, Beat Bornhauser, Jean-Pierre Bourquin, Vaskar Saha, Shekhar Krishnan

Blood (2023) 142 (Supplement 1): 4244.

https://doi.org/10.1182/blood-2023-185989

Published: 2023

Journal Articles

IKZF1 Deletions Induce Resistance to AraC in BCP-ALL Reversible By CDK8/19 Inhibition

Britt M T Vervoort, Miriam Butler, Dorette van Ingen Schenau, Vincent H.J. van der Velden, Beat Bornhauser, Jean-Pierre Bourquin, Laurens T van der Meer, Frank N van Leeuwen

Blood (2022) 140 (Supplement 1): 3465–3466.

https://doi.org/10.1182/blood-2022-162246

Published: 2022

Journal Articles

The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of Action

Lennart Lenk, Irène Baccelli, Dorothee Winterberg, Anna Dietterle, Frédérique Corallo, Julien Taurelle, Emma Narbeburu, Anna Laqua, Beat Bornhauser, Jean-Pierre Bourquin, Fotini Vogiatzi, Martin Schrappe, Gunnar Cario, Monika Brüggemann, Nicolas Poirier, Denis Martin Schewe

Blood (2022) 140 (Supplement 1): 1045–1047.

https://doi.org/10.1182/blood-2022-162261

Published: 2022

Journal Articles

Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL

Blood (2022) 140 (1): 45–57.

https://doi.org/10.1182/blood.2021014485

Published: 2022

Includes: Supplemental data

Journal Articles

BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway

Miriam Butler, Dorette S. van Ingen Schenau, Jiangyan Yu, Silvia Jenni, Maria P. Dobay, Rico Hagelaar, Britt M. T. Vervoort, Trisha M. Tee, Fieke W. Hoff, Jules P. Meijerink, Steven M. Kornblau, Beat Bornhauser, Jean-Pierre Bourquin, Roland P. Kuiper, Laurens T. van der Meer, Frank N. van Leeuwen

Blood (2021) 138 (23): 2383–2395.

https://doi.org/10.1182/blood.2021011787

Published: 2021

Includes: Supplemental data

Journal Articles

14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia

Blood (2021) 138 (9): 773–784.

https://doi.org/10.1182/blood.2020010510

Published: 2021

Includes: Supplemental data

Journal Articles

Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia

Fotini Vogiatzi, PhD, Kristina Müller, Dorothee Winterberg, Thies Rösner, PhD, Lennart Lenk, PhD, Gunnar Cario, MD PhD, Martin Schrappe, MDPhD, Andreas E. Kulozik, MD PhD, Beat Bornhauser, Jean-Pierre Bourquin, MD PhD, Thomas Valerius, MD, Matthias Peipp, PhD, Christian Kellner, PhD, Denis Martin Schewe, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-140270

Published: 2020

Journal Articles

The Central Role of MAPK-ERK Signaling in IL7-Dependent and IL7-Independent Steroid Resistance Reveals a Broad Application of MEK-Inhibitors Compared to JAK1/2-Inhibition in T-ALL

Jordy C.G. Van Der Zwet, MD, Jessica G.C.A.M. Buijs-Gladdines, Valentina Cordo', MSc, Donna Debets, MSc, Willem K. Smits, Zhongli Chen, MSc, Jelle Dylus, Guido Zaman, PhD, Maarten Altelaar, PhD, Koichi Oshima, MD PhD, Beat Bornhauser, Jean-Pierre Bourquin, MD PhD, Jan Cools, PhD, Adolfo A. Ferrando, MD PhD, Josef Vormoor, MD PhD, Rob Pieters, MDPhDMSc, Britta Julia Vormoor, MD, Jules P.P. Meijerink, PhD

Blood (2020) 136 (Supplement 1): 20.

https://doi.org/10.1182/blood-2020-139305

Published: 2020

Journal Articles

In Vitro Drug Response Profiling in BCP- and T-ALL Primary Samples Adds a Robust Functional Layer Enabling Optimized Guidance of Individualized Therapy in Relapsed and Refractory Pediatric Acute Leukemia Patients

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-142314

Published: 2020

Journal Articles

Inducible Phase Separation of GSK3α As a Mechanism for Asparaginase Resistance in Acute Leukemias

Laura Hinze, Sabine Schreek, Andre Zeug, PhD, Evgeni Ponimaskin, PhD, Roxane Labrosse, MD FRCPC, James Degar, Gabriela Chiosis, PhD, Sung-Yun Pai, MD, Kristen E. Stevenson, MS, Donna S Neuberg, ScD, Beat Bornhauser, PhD, Jean-Pierre Bourquin, MD PhD, Martin Stanulla, MD, Alejandro Gutierrez, MD

Blood (2019) 134 (Supplement_1): 169.

https://doi.org/10.1182/blood-2019-126633

Published: 2019

Journal Articles

Venetoclax Enhances the Efficacy of Therapeutic Antibodies in B-Cell Malignancies

Fotini Vogiatzi, PhD, Julia Heymann, Thies Rösner, PhD, Lennart Lenk, PhD MSc, Gunnar Cario, MD, Martin Schrappe, MD PhD, Beat Bornhauser, PhD, Jean-Pierre Bourquin, MD PhD, Simon Bomken, MD, Thomas Valerius, MD, Matthias Peipp, PhD, Christian Kellner, PhD, Denis Martin Schewe, MD

Blood (2018) 132 (Supplement 1): 4177.

https://doi.org/10.1182/blood-2018-99-114677

Published: 2018

Journal Articles

Pediatric T-ALLs Developing into a Type 2 Relapse Originate from Cells That Carry the Potential of Variable Maturation into Subclones with Distinct Chromatin Landscapes

Blood (2018) 132 (Supplement 1): 1545.

https://doi.org/10.1182/blood-2018-99-118255

Published: 2018

Journal Articles

The Chromosome 21 Kinase DYRK1A and Its Substrate FOXO1 Constitute a Novel Therapeutic Pathway in B-ALL

Rahul S. Bhansali, Malini Rammohan, MS, Ji Heon Paul Lee, MD PhD, Sebastien Malinge, PhD, Yi-Chien Tsai, Nobuko Hijiya, MD, Beat Bornhauser, PhD, Jean-Pierre Bourquin, MD PhD, Corinne Fruit, Thierry Besson, PhD, John D. Crispino, PhD MBA

Blood (2018) 132 (Supplement 1): 548.

https://doi.org/10.1182/blood-2018-99-119854

Published: 2018

Journal Articles

Longitudinal Multilevel Omic Analysis of Pediatric T-ALL Reveals Distinct Mechanisms for Disease Progression in Type 1 and in Type 2 Relapses

Blood (2018) 132 (Supplement 1): 2826.

https://doi.org/10.1182/blood-2018-99-117978

Published: 2018

Journal Articles

A CRISPR/Cas9 Based Kinome Screen Identifies Bruton Tyrosine Kinase (BTK) As an Important Determinant of Asparaginase Treatment Response in Acute Lymphoblastic Leukemia

Miriam Butler, MSc, Laurens Van Der Meer, PhD, Jiangyan Yu, Silvia Jenni, PhD, Maria Pamela Dobay, PhD, Peter Hoogerbrugge, MD, Beat Bornhauser, PhD, Jean-Pierre Bourquin, MD PhD, Roland P. Kuiper, PhD, Frank van Leeuwen, PhD

Blood (2017) 130 (Supplement 1): 34.

https://doi.org/10.1182/blood.V130.Suppl_1.34.34

Published: 2017

Journal Articles

TCF3-Hlf Hijacks ERG to Activate Leukemia-Critical Super-Enhancers in t(17;19) Leukemia

Yun Huang, PhD, Brice Mouttet, Hans-Jörg Warnatz, PhD, Maria Pamela Dobay, PhD, Blerim Marovca, Silvia Jenni, PhD, Martin Schrappe, MD PhD, Martin Stanulla, MD PhD, Marie-Laure Yaspo, Beat Bornhauser, PhD, Jean-Pierre Bourquin, MD PhD

Blood (2017) 130 (Supplement 1): 561.

https://doi.org/10.1182/blood.V130.Suppl_1.561.561

Published: 2017

Journal Articles

PDX Models Recapitulate Genetics and Epigenetics of Pediatric T-Cell Leukemia

Blood (2017) 130 (Supplement 1): 2723.

https://doi.org/10.1182/blood.V130.Suppl_1.2723.2723

Published: 2017

NARROW

The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis

Drug Response Profiling Informs Personalized Bridging to Cell Therapy for Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Phenotypic Drug Response Profiling Identifies Asparaginase-Based Synergistic Combinations for Very High Risk Acute Lymphoblastic Leukaemia

Delayed Intensification Including Venetoclax and Bortezomib Prolongs Survival in Very High Risk Acute Lymphoblastic Leukaemia

IKZF1 Deletions Induce Resistance to AraC in BCP-ALL Reversible By CDK8/19 Inhibition

The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of Action

Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL

BTK inhibition sensitizes acute lymphoblastic leukemia to asparaginase by suppressing the amino acid response pathway

14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia

Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia

The Central Role of MAPK-ERK Signaling in IL7-Dependent and IL7-Independent Steroid Resistance Reveals a Broad Application of MEK-Inhibitors Compared to JAK1/2-Inhibition in T-ALL

In Vitro Drug Response Profiling in BCP- and T-ALL Primary Samples Adds a Robust Functional Layer Enabling Optimized Guidance of Individualized Therapy in Relapsed and Refractory Pediatric Acute Leukemia Patients

Inducible Phase Separation of GSK3α As a Mechanism for Asparaginase Resistance in Acute Leukemias

Venetoclax Enhances the Efficacy of Therapeutic Antibodies in B-Cell Malignancies

Pediatric T-ALLs Developing into a Type 2 Relapse Originate from Cells That Carry the Potential of Variable Maturation into Subclones with Distinct Chromatin Landscapes

The Chromosome 21 Kinase DYRK1A and Its Substrate FOXO1 Constitute a Novel Therapeutic Pathway in B-ALL

Longitudinal Multilevel Omic Analysis of Pediatric T-ALL Reveals Distinct Mechanisms for Disease Progression in Type 1 and in Type 2 Relapses

A CRISPR/Cas9 Based Kinome Screen Identifies Bruton Tyrosine Kinase (BTK) As an Important Determinant of Asparaginase Treatment Response in Acute Lymphoblastic Leukemia

TCF3-Hlf Hijacks ERG to Activate Leukemia-Critical Super-Enhancers in t(17;19) Leukemia

PDX Models Recapitulate Genetics and Epigenetics of Pediatric T-Cell Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only